#London #United Kingdom #Coronado Research #Gary Lyons #Medical Affairs

Coronado Research Welcomes Gary Lyons as EVP of Medical Affairs

Coronado Research has recently appointed Gary Lyons as the new Executive Vice President of Medical Affairs, a strategic move designed to strengthen and enhance the company’s capabilities in medical communications and cross-functional collaboration in the pharmaceutical industry. With over two decades of experience, Gary brings a wealth of knowledge in leading Medical Affairs initiatives across various sectors, ensuring the alignment of clinical development with commercial strategies.

Gary has previously held significant roles where he successfully led agency business units and formulated specialized teams focusing on superior medical communication services. His work has spanned both global and local levels, emphasizing innovation and strategic implementation. As Coronado Research continues to evolve, Gary's expertise is expected to play a pivotal role in optimizing drug development and commercialization processes.

Andrew MacGarvey, the CEO of Coronado Research, expressed his enthusiasm for Gary's appointment, noting, "Gary brings a passion and wealth of knowledge for transforming medical affairs. This aligns perfectly with Coronado’s mission of maximizing outcomes for patients by optimizing drug development and commercialization." He underlined that Gary's experience from high-level positions in the Pharmaceutical and Consultancy sectors will be vital in formulating strategically optimized solutions for clients. By fostering a bridge between clinical development and commercial teams, the Medical Affairs function will be positioned as a key player in integrative service delivery.

In response, Gary Lyons highlighted the importance and role of Medical Affairs, stating, "Medical Affairs is a central and critical function within pharma, increasingly bridging clinical development and commercial teams. Working cross-functionally, Medical Affairs optimizes trial design, translates clinical data into impactful narratives, and ensures evidence is robust across the drug lifecycle." He emphasized the growing need for Medical Affairs to engage stakeholders with pertinent data and evidence, all while employing personalized approaches through cross-functional collaboration.

Under Gary’s leadership, Coronado Research is set to harness its integrated capabilities, which are built from the ground up to address cross-functional needs across clinical development, market access, and regulatory affairs. The company’s innovative approach combines advanced technologies like Artificial Intelligence and automation, reinforcing the human aspect at the core of its operations. This alignment is crucial for maximizing evidence generation and enhancing stakeholder engagement throughout the medical planning and operational processes.

Gary further expressed his commitment to developing an outstanding Medical Affairs capability, stressing that success will come from a focus on strategic excellence and precise execution, all driven by a passion for science and its effective communication.

About Coronado Research

Coronado Research is a consultancy-led organization that provides specialized services to pharmaceutical, biotechnology, and medical device companies. Their goal is to optimize clinical development by leveraging available data, utilizing AI, Machine Learning, and the latest technologies. The firm focuses on connecting various disciplines, including Regulatory Strategy, Advanced Analytics, Medical Affairs, Market Access, and Health Economics, ensuring that treatments align with market needs effectively. For more information, interested parties are encouraged to reach out directly to Coronado Research.